ulcerative colitis
Conditions
Interventions
Patients treated with leukocytapheresis (more than once per week, total 10 sessions) therapy have a regular blood test
Sponsors
Kyoto University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with moderate, severe or intractable ulcerative colitis 2) Patients with ulcerative colitis of left side colitis or pancolitis type 3) Patients whom immunomodulator doses are not changed for two months 4) Patients that steroid doses are not increased in quantity for one week
Exclusion criteria
Exclusion criteria: 1) Patients with proctitis 2) Patients with either white blood cell count of less than 3,000/mm3, or hemoglobin level of less than 10g/dL, or platelet count of less than 100,000/mm3 3) Patients with fulminating active ulcerative colitis (massive bleeding, perforation, toxic megacolon) 4) Patients with serious infection or cardiovascular disease or liver disease or kidney disease or respiratory disease or metabolic disease neurologic disease 5) Patients with hypotension (less than maximal blood pressure 80mmHg) 6) Patients with allergic anamnesis or experience or the fear of allergic hypersensitivity reaction 7) Patients having received inhibitor of angiotensin converting enzyme 8) Patients who are pregnant or have the possibility of pregnancy 9) Patients who are younger than 12 years old or low weight 10) Patients determined to be inappropriate for this study by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CXCR4 expression on CD4 positive T cell in peripheral blood | — |
Countries
Japan
Contacts
Public ContactMinoru Matsuura
Kyoto University Hospital Department of Gastroenterology and Hepatology
Outcome results
None listed